a) Clostridioides difficile infeksjon - nytt sykdoms område for tarm mikrobiota analyse

Offentlig prosjektsammendrag

Clostridium difficile infection (CDI) is a disease with symptoms ranging from mild diarrhea to severe life-threatening inflammation of the colon, generally in connection with a severe disturbance of the composition of intestinal microbiota. In the US, CDI is a very common disease, affecting approximately 500,000 patients annually, and of these around 30,000 will die from the disease. Live Biotherapeutic Products (LBP), are new alternative types of therapeutics, intended for the prevention of recurrence of CDI, by restoring the patients’ microbiota to a healthier condition. In this project, Genetic Analysis expertise in the microbiota field will be utilized to develop an easy-to-use, in vitro diagnostic test, by gut bacteria profile recognition, technical and clinical validation, and SW algorithm development. This will provide actionable results to allow for informed decisions regarding disease management and treatment and can be easily accessed by healthcare professionals.